// App-Quantinova.ai

: Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Researchers

Presenter

  • Yuan Jian

Principal Investigators

  • Mingxia Shi

  • Ying Sun

  • Xiaoxia Chu

  • Hua Xue

  • Wenrong Huang

  • Xuliang Shen

  • Jie Ma

  • Guorong Jia

  • Yaqing Feng

  • Zhenfang Xi

  • Yanhong Zhao

  • Yanping Ma

  • Jing Xiao

  • Guangyu Ma

  • Qingming Wang

  • Li Bao

  • Yujun Dong

  • Hebing Zhou

  • Chunyan Sun

  • Guohong Su

  • Yan Yan

  • Saiyin Qimuge

  • Liping Su

  • Jingnan Sun

  • Weiwei Tian

  • Xiuli SUN

  • Hongmei Jing

  • Da Gao

  • Wenming Chen

  • Jian Li

  • Wen Gao

Medical Centers

  • Department of Hematology, Beijing Luhe Hospital,Capital Medical University, Beijing, China

  • The First Hospital of Jilin University, Changchun, China

  • The Second Hospital of Hebei Medical University, Hebei, China

  • Yantaishan Hospital Affiliated to Binzhou Medical University, Yantai, China

  • The First Affiliated Hospital, Harbin Medical University, Harbin, China

  • The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Secience and Technology, Baotou, China

  • Ordos Central Hospital, Ordos, China

  • Beijing Chaoyang Hospital, Capital medical University, BEIJING, China

  • Department of Hematology, Third Hospital of Peking University, Beijing, China

  • The First Affiliated Hospital of Kunming Medical University, Hematology Research Center of Yunnan Province, Kunming, China

  • Linfen People's Hospital, Linfen, China

  • The Second Affiliated Hospital of Nanchang University, Nanchang, China

  • Chifeng Municipal Hospital, Chifeng, China

  • Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China

  • The Third People's Hospital Of Datong, Datong, China

  • Shanxi Bethune Hospital, Taiyuan, China

  • Department of Hematology, Shanxi Cancer Hospital, Taiyuan, China

  • Department of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Beijing, China

  • The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

  • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • The Affiliated Hospital of Inner Mongolia Medical University, Huhhot, China

  • Department of Hematology, Yantai Yuhuangding Hospital, Yantai, Shandong, China

  • Bayannur Hospital, Bayannur, China

  • The Forth Hospital of Hebei Medical University, Shijiazhuang, China

  • The Fifth Medical Center of the General Hospital of the Chinese people's Liberation Army, Beijing, China

  • Cangzhou Central Hospital, Cangzhou, China

  • Department of Hematology, Peking University First Hospital, Beijing, China

  • Department of Hematology, the Second Hospital of Shanxi Medical University, taiyuan, China

  • Union Hospital,Tongji Medical College,Huazhong University of Science and Technology, Wuhan, China

  • Beijing Jishuitan Hospital, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Multiple Myeloma

  • Renal insufficiency

  • Renal disease

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Bortezomib

Outcome

  • N/A

Study Design

  • Safety

  • Open Label

  • Multinational

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved